IL1B and Cognitive impairment: Since acute cognitive impairments following systemic LPS were immediately preceded by robust circulating IL-1β, we hypothesised that systemic IL-1β contributed to these deficits and we therefore assessed whether peripheral treatment with the receptor antagonist IL-1RA would protect against the T-maze and CFC deficits described in Fig. 1.